# Cohort Event Monitoring Study of Pyramax®

> **NCT03201770** · PHASE4 · COMPLETED · sponsor: **Shin Poong Pharmaceutical Co. Ltd.** · enrollment: 8572 (actual)

## Conditions studied

- Malaria,Falciparum

## Interventions

- **DRUG:** pyronaridine artesunate

## Key facts

- **NCT ID:** NCT03201770
- **Lead sponsor:** Shin Poong Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-22
- **Primary completion:** 2019-04-10
- **Final completion:** 2019-04-10
- **Target enrollment:** 8572 (ACTUAL)
- **Last updated:** 2019-06-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03201770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03201770, "Cohort Event Monitoring Study of Pyramax®". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03201770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*